Fig. 6
From: TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L
CIC, ATXN1L, and TRIM25 regulate cell cycle in vitro and in TCGA patient data. a Barplot displaying the frequency of TRIM25 alterations in the TCGA Pan-Cancer study. Bars represent a cancer subtype and split based on alteration type. b Scatter plot showing the Log2Fold change of differentially expressed genes shared between TRIM25 siRNA in BT549 and MDA-MB-231 breast cancer cell lines and CIC/ATXN1L knockout in NHA cell lines. Differentially expressed genes with directionally discordant change are colored (red/blue). c Scatter plot showing the Log2Fold change of differentially expressed genes shared between TCGA BRCA samples with TRIM25 amplification and TCGA type II LGG, PRAD, and STAD samples with CIC deletions. Differentially expressed genes with directionally concordant change are colored (red/blue). d Heatmap showing the top 20 enriched gene sets for directionally concordant upregulated differentially expressed genes shared between TCGA BRCA samples with TRIM25 amplification and TCGA type II LGG, PRAD, and STAD samples with CIC deletions. Highlighted terms are terms related to the cell cycle. e Kaplan-Meier curve showing the overall survival of TCGA BRCA patients with high (top 25%) and low (bottom 75%) TRIM25 expression. f Tukey barplots showing the expression of TRIM25, ETV1, ETV4, and ETV5 in TCGA LIHC samples with high (top 25%) and low (bottom 75%) TRIM25 expression. g Kaplan-Meier curve showing the overall survival of TCGA LIHC patients with high (top 25%) and low (bottom 75%) TRIM25 expression. Statistically significant values are denoted (*p < 0.05, **p < 0.01, ***p < 0.001)